Research and Development Expenditure
First written in FY2018-Q1. 23 of 33 entries say "Advanced", first in FY2018-Q2. Latest entry: FY2026.
56 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Total research and development expenses for the consolidated fiscal year were ¥16,292 million.」
Research and development expenses amounted to ¥16,292 million, up from ¥11,677 million in the previous fiscal year. R&D investment increased, including investment in the development of new products such as EUV, wafers and masks. - 2026-08-06AdvancedRevision of earnings forecasts
「Research and development expenses 11,677 16,292」
Research and development expenses increased from ¥11.677 billion in the previous fiscal year to ¥16.292 billion in the current fiscal year. - FY2026-H1AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the interim consolidated accounting period was ¥6,511 million. There were no material changes in the status of the Group's research and development activities during the interim consolidated accounting period.」
Research and development activities amounted to ¥6,511 million for the interim period, up from ¥4,314 million in the same period of the previous year. The statement that there were no material changes in the status of research and development activities has been maintained. - FY2025Decrease in R&D expensesAnnual report
「Total research and development expenses for the consolidated fiscal year were ¥11,677 million.」
Research and development expenses amounted to ¥11,677 million, down from ¥12,165 million in the previous fiscal year. The company continued developing new products, including EUV, SiC wafers and battery-related products. - FY2025-H1Continued decline in research and development expensesAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the interim consolidated accounting period was ¥4,314 million. There were no material changes in the status of the Group's research and development activities during the interim consolidated accounting period.」
Research and development activities amounted to ¥4,314 million for the interim period, down approximately 11.3% from ¥4,861 million in the same period of the previous year. The company stated that there were no material changes in the status of its research and development activities. - FY2024AdvancedAnnual report
「Total research and development expenses for the consolidated fiscal year were ¥12,165 million.」
Research and development expenses amounted to ¥12,165 million, up 10.8% from ¥10,977 million in the previous fiscal year. The funds were used for the development and performance improvements of EUV mask defect inspection systems and other products. - FY2024-Q3Continued decline in research and development expensesAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the third quarter cumulative consolidated period was ¥7,906 million. There were no material changes in the status of the Group's research and development activities during the third quarter cumulative consolidated period.」
Research and development activities amounted to ¥7,906 million for the third quarter cumulative period, down from ¥8,079 million in the same period of the previous year. The statement that there were no material changes in the status of research and development activities has been maintained. - FY2024-Q2Continued decline in research and development expensesAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the second quarter cumulative consolidated period was ¥4,861 million. There were no material changes in the status of the Group's research and development activities during the second quarter cumulative consolidated period.」
Research and development activities amounted to ¥4,861 million for the second quarter cumulative period, down from ¥6,221 million in the same period of the previous year. The company stated that there were no material changes in the status of its research and development activities. - FY2024-Q1Slight decline in R&D expensesAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the first quarter cumulative consolidated period was ¥2,354 million. There were no material changes in the status of the Group's research and development activities during the first quarter cumulative consolidated period.」
Research and development activities amounted to ¥2,354 million, a slight decrease from ¥2,415 million in the same period of the previous year. The company stated that there were no material changes in the status of its research and development activities. - FY2023AdvancedAnnual report
「Total research and development expenses for the consolidated fiscal year were ¥10,977 million.」
Research and development expenses amounted to ¥10,977 million, up 27.2% from ¥8,626 million in the previous fiscal year. The funds were used for the development and performance improvements of EUV mask defect inspection systems and other products. - FY2023-Q3AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the third quarter cumulative consolidated period was ¥8,079 million. There were no material changes in the status of the Group's research and development activities during the third quarter cumulative consolidated period.」
Research and development activities amounted to ¥8,079 million for the third quarter cumulative period, up from ¥6,443 million in the same period of the previous year. - FY2023-Q2AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the second quarter cumulative consolidated period was ¥6,221 million.」
Research and development activities amounted to ¥6,221 million for the second quarter cumulative period, up from ¥3,823 million in the same period of the previous year. - FY2023-Q1AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the first quarter cumulative consolidated period was ¥2,415 million. There were no material changes in the status of the Group's research and development activities during the first quarter cumulative consolidated period.」
Research and development activities amounted to ¥2,415 million, up from ¥2,143 million in the same period of the previous year. The statement that there were no material changes in the status of research and development activities has also been maintained. - FY2022AdvancedAnnual report
「Total research and development expenses for the consolidated fiscal year were ¥8,626 million.」
Research and development expenses amounted to ¥8,626 million, up 51.2% from ¥5,706 million in the previous fiscal year. The funds were used for the development and performance improvements of EUV mask defect inspection systems and other products. - FY2022-Q3AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the third quarter cumulative consolidated period was ¥6,443 million. There were no material changes in the status of the Group's research and development activities during the third quarter cumulative consolidated period.」
Research and development activities amounted to ¥6,443 million for the third quarter cumulative period, up approximately 75.8% from ¥3,665 million in the same period of the previous year. The statement that there were no material changes in the status of research and development activities has also been maintained. - FY2022-Q2AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the second quarter cumulative consolidated period was ¥3,823 million.」
Research and development activities amounted to ¥3,823 million for the second quarter cumulative period, up from ¥2,029 million in the same period of the previous year. The company also stated that there were no material changes in the status of its research and development activities. - FY2022-Q1AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the first quarter cumulative consolidated period was ¥2,143 million. There were no material changes in the status of the Group's research and development activities during the first quarter cumulative consolidated period.」
Research and development activities amounted to ¥2,143 million, approximately double the ¥1,071 million recorded in the same period of the previous year. The company also stated that there were no material changes in the status of its research and development activities. - FY2021AdvancedAnnual report
「Total research and development expenses for the consolidated fiscal year were ¥5,706 million.」
Research and development expenses amounted to ¥5,706 million, up 73.0% from ¥3,297 million in the previous fiscal year. The funds were used mainly for the development and performance improvements of EUV mask defect inspection systems and other products. - FY2021-Q3AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the third quarter cumulative consolidated period was ¥3,665 million. There were no material changes in the status of the Group's research and development activities during the third quarter cumulative consolidated period.」
Research and development activities amounted to ¥3,665 million for the third quarter cumulative period, up from ¥2,300 million in the same period of the previous year. The statement that there were no material changes in the status of research and development activities has also been maintained. - FY2021-Q2AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the second quarter cumulative consolidated period was ¥2,029 million. There were no material changes in the status of the Group's research and development activities during the second quarter cumulative consolidated period.」
Research and development activities amounted to ¥2,029 million for the second quarter cumulative period, exceeding ¥1,920 million in the same period of the previous year and ¥1,445 million in the previous quarter cumulative period. The company also stated that there were no material changes in the status of its research and development activities. - FY2021-Q1R&D expense growth resumesAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the first quarter cumulative consolidated period was ¥1,071 million. There were no material changes in the status of the Group's research and development activities during the first quarter cumulative consolidated period.」
Research and development activities amounted to ¥1,071 million for the first quarter cumulative period, up from ¥703 million in the same period of the previous year. On a quarterly basis, R&D spending has turned upward after the declining trend that continued through FY2020. - FY2020Continued decline in research and development expensesAnnual report
「Total research and development expenses for the consolidated fiscal year were ¥3,297 million.」
Research and development expenses amounted to ¥3,297 million, down 8.2% from ¥3,590 million in the previous fiscal year. The company stated that, partly due to the impact of COVID-19, the amount fell short of the initial forecast. - FY2020-Q3Decrease in R&D expensesAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the third quarter cumulative consolidated period was ¥2,300 million. There were no material changes in the status of the Group's research and development activities during the third quarter cumulative consolidated period.」
Research and development activities amounted to ¥2,300 million for the third quarter cumulative period, down from ¥2,758 million in the same period of the previous year. The company stated that there were no material changes in the status of its research and development activities. - FY2020-Q2Decrease in R&D expensesAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the second quarter cumulative consolidated period was ¥1,445 million. There were no material changes in the status of the Group's research and development activities during the second quarter cumulative consolidated period.」
Research and development activities amounted to ¥1,445 million for the second quarter cumulative period, down from ¥1,920 million in the same period of the previous year. The company stated that there were no material changes in the status of its research and development activities. - FY2020-Q1AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the first quarter cumulative consolidated period was ¥703 million. There were no material changes in the status of the Group's research and development activities during the first quarter cumulative consolidated period.」
Research and development activities amounted to ¥703 million for the first quarter cumulative period, up from ¥501 million in the same period of the previous year. The company also stated that there were no material changes in the status of its research and development activities. - FY2019AdvancedAnnual report
「Research and development expenses primarily comprised the development of new semiconductor-related products and new models of the company's current mainstay products, including mask defect inspection systems and mask blank defect inspection systems. They amounted to ¥3,590 million, up 29.5% from the previous consolidated fiscal year.」
Research and development expenses amounted to ¥3,590 million, up 29.5% from the previous fiscal year. R&D investment increased mainly for the development of new semiconductor-related products and new models of core equipment. - FY2019-Q3AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the third quarter cumulative consolidated period was ¥2,758 million. There were no material changes in the status of the Group's research and development activities during the third quarter cumulative consolidated period.」
Research and development activities amounted to ¥2,758 million for the third quarter cumulative period, up from ¥2,124 million in the same period of the previous year. The company also stated that there were no material changes in the status of its research and development activities. - FY2019-Q2AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the second quarter cumulative consolidated period was ¥1,920 million.」
Research and development activities amounted to ¥1,920 million for the second quarter cumulative period, up from ¥1,129 million in the same period of the previous year. The company also stated that there were no material changes in the status of its research and development activities. - FY2019-Q1AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the first quarter cumulative consolidated period was ¥1,111 million. There were no material changes in the status of the Group's research and development activities during the first quarter cumulative consolidated period.」
Research and development activities amounted to ¥1,111 million for the first quarter cumulative period, up from ¥501 million in the same period of the previous year. The company also stated that there were no material changes in the status of its research and development activities. - FY2018AdvancedAnnual report
「Total research and development expenses for the consolidated fiscal year were ¥2,772 million.」
Research and development expenses amounted to ¥2,772 million, an increase of 89.7% from ¥1,461 million in the previous fiscal year. - FY2018-Q3AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the third quarter cumulative consolidated period was ¥2,124 million.」
Research and development activities amounted to ¥2,124 million for the third quarter cumulative period, up from ¥1,129 million for the second quarter cumulative period. - FY2018-Q2AdvancedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the second quarter cumulative consolidated period was ¥1,129 million.」
Research and development activities amounted to ¥1,129 million for the second quarter cumulative period, up from ¥970 million in the same period of the previous year. - FY2018-Q1First statedAnnual report
「The amount of research and development activities undertaken by the Group as a whole during the first quarter cumulative consolidated period was ¥501 million.」
The Group's research and development activities amounted to ¥501 million for the first quarter cumulative period, up from ¥501 million in the same period of the previous year.